Traders Buy Large Volume of Call Options on BioNTech (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the target of unusually large options trading activity on Tuesday. Stock investors purchased 4,599 call options on the stock. This is an increase of 58% compared to the typical volume of 2,906 call options.

BioNTech Stock Down 3.7 %

Shares of BNTX opened at $122.15 on Thursday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a market cap of $29.28 billion, a PE ratio of -58.17 and a beta of 0.18. The business has a fifty day moving average of $113.89 and a 200 day moving average of $102.93.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the prior year, the company posted $0.73 EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, sell-side analysts expect that BioNTech will post -3.72 EPS for the current year.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently made changes to their positions in the business. Planning Capital Management Corp grew its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after acquiring an additional 450 shares in the last quarter. Blue Trust Inc. grew its position in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares during the period. Finally, Caprock Group LLC bought a new position in BioNTech during the 2nd quarter worth about $206,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on BNTX. Wells Fargo & Company initiated coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price on the stock. Berenberg Bank initiated coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. HSBC upped their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Finally, JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $140.76.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.